| editorial | Q871232 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/QAD.0B013E3283136D95 |
| P698 | PubMed publication ID | 18981762 |
| P50 | author | Gerd Fätkenheuer | Q47006694 |
| Giuseppe Tambussi | Q47158634 | ||
| Vicente Soriano | Q55277832 | ||
| Deenan Pillay | Q57899870 | ||
| P2093 | author name string | Jacques Reynes | |
| Vincent Calvez | |||
| Carlo-Federico Perno | |||
| José Alcamí | |||
| Juergen Rockstroh | |||
| Anna María Geretti | |||
| P2860 | cites work | Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells | Q28270680 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2231-2240 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | AIDS | Q4651863 |
| P1476 | title | Optimal use of maraviroc in clinical practice | |
| P478 | volume | 22 |
| Q36168754 | Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS. |
| Q35573197 | Chemokine co-receptor usage in HIV-1-infected treatment-naïve voluntary counselling and testing clients in Southern Taiwan |
| Q37486616 | Chemokines as therapeutic targets for atherosclerotic plaque destabilization and rupture |
| Q38833823 | Critical roles of chemokine receptor CCR5 in regulating glioblastoma proliferation and invasion |
| Q41991922 | Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients |
| Q38970509 | Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. |
| Q34235156 | Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials |
| Q34103125 | In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection |
| Q45362666 | In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells |
| Q42140292 | Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors |
| Q37421895 | Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. |
| Q38042334 | Prevalence of drug interactions in hospital healthcare. |
| Q45932455 | Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. |
| Q51859231 | Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. |
| Q37733565 | Treatment of HIV infection with the CCR5 antagonist maraviroc |
| Q24642446 | Virus maturation as a new HIV-1 therapeutic target |
Search more.